Monday 30th August 2021
|Text too small?|
Rua Bioscience announces its annual financial results for the 12 months ended 30 June 2021 (FY21). In FY21, Rua's focus has been on building solid foundations for growth – developing the partnerships, places, processes, and people it needs to create a sustainable medicinal cannabis business model.
Rua’s commitment to creating shareholder value has seen it working on two fronts - preparing to enter local and global medicinal cannabis markets by calendar year end 2021 / early 2022 and developing long-term opportunities across the medicinal cannabis value chain.
Rua Bioscience is a pharmaceutical company aiming to lead the production of cannabinoid-derived medicines. The Company has a focused and realistic export strategy, with a clear path to revenue and a view extending along the medicinal cannabis value chain. Proceeds from the IPO continue to fund Rua Bioscience's next growth stage, building long-term resilience and accelerating growth.
Please see the links below for details
No comments yet
17th September 2021 Morning Report
NZ Automotive Investments Limited (NZX: NZA) Proposed Sell Down by NZA Founder to Improve Liquidity
16th September 2021 Morning Report
15th September 2021 Morning Report
Seeka Limited (NZX: SEK) Announces Further Kiwifruit Acquisition
Briscoe Group Limited (NZX: BGP) Half Year Results Announcement
14th September 2021 Morning Report
Stride Property Ltd & Stride Investment Management Ltd (NZX: SPG) Office Fund Established and Conditional Acquisition
Third Age Health Services Limited (NZX: TAH) Announces Acquisition of Belmont Medical
13th September 2021 Morning Report